As the use of technologies in the life sciences industry continues to evolve, the need for efficient and compliant computer system validation (CSV) remains a top priority. CSV ensures that systems used as part of the Production and as part of the Quality system meet regulatory standards, maintain data integrity, ensure product quality, and safeguard patient safety.
In 2026, emerging computer system validation trends are redefining CSV methodologies and tools, allowing organizations to improve efficiency, reduce costs, and enhance compliance. In this article, we explore the trends that matter most and how technology and modern methodologies are transforming CSV processes.
The US Food and Drug Administration (FDA) revised its computer software assurance (CSA) guidance. The European Union (EU) is revising Annex 11 and drafting Annex 22. Artificial intelligence (AI) is also arriving in validation tooling.
We compiled these computer system validation trends from Darren Geaney’s 23+ years in CSV practice and audits. They also draw on the 2026 State of Validation survey of 614 professionals. We reviewed FDA’s CSA guidance, the draft Annex 11 and Annex 22, and the International Society for Pharmaceutical Engineering’s (ISPE) GAMP 5 Second Edition.
Key takeaways on computer system validation trends in 2026
- FDA’s nonbinding CSA guidance, revised on February 3, 2026, makes risk-based assurance the default for medical device production and quality management system software.
- As of October 6, 2026, the EU has not adopted revised Annex 11 or new Annex 22; EudraLex lists the January 2011 Annex 11.
- The 2026 State of Validation shows 64% of organizations using or implementing a dedicated digital validation solution.
- Validation teams are adopting AI for good practice (GxP) validation, with 39% using or evaluating it and 78% expecting it to be standard by 2030.
- Kneat Gx is a cloud-based digital validation platform that manages the full CSV lifecycle in a 21 CFR Part 11 and Annex 11 compliant system.
1. Risk-based validation becomes the baseline under FDA CSA
The adoption of risk-based validation is transforming CSV by focusing resources on the most critical areas that impact product quality and patient safety. This approach, in line with the FDA’s computer software assurance (CSA) framework, encourages companies to prioritize validation activities based on risk assessment, rather than treating all systems with equal scrutiny. By concentrating on high-risk areas, organizations can reduce the time and cost of validation while still ensuring full compliance.
A risk-based strategy allows validation teams to make more strategic decisions and allocate resources effectively. For example, systems that pose minimal risk to patient safety may require less rigorous testing, while critical systems undergo more thorough validation. This targeted approach improves validation efficiency and ensures that companies meet regulatory requirements without unnecessary overhead.
FDA issued its final CSA guidance on September 24, 2025, following a 2022 draft. On February 3, 2026, FDA revised it as Computer Software Assurance for Production and Quality Management System Software. The revision aligns the guidance with the Quality Management System Regulation (QMSR), which took effect on February 2, 2026.
Our breakdown of FDA’s final CSA guidance walks through each section. In summary, the framework asks manufacturers to:
- Identify the intended use of the software.
- Determine the risk-based approach.
- Select the appropriate assurance activities.
- Establish the appropriate record.
Under the revised guidance, for features that are not high process risk, manufacturers “may consider” unscripted methods like scenario (ad hoc), error-guessing, and exploratory testing. Documentation “need not include more evidence than necessary” to show a feature performs as intended for the risk identified. FDA also recommends digital records, such as system logs and audit trails, over screenshots.
The guidance is nonbinding and covers medical device production and quality management system (QMS) software. It is not a drug good manufacturing practice (GMP) requirement under 21 CFR Part 211. Pharma and biotech teams commonly apply its principles through GAMP 5 Second Edition’s risk-based, critical-thinking approach.
Adopting a CSA approach provides organizations with flexibility and agility in helping ensure that the software is maintained in a validated state. These findings indicate that validation professionals should focus on supporting organizations through the adoption phase and addressing barriers to full integration. Once adopted, professionals should focus on compliance, best practices, and ongoing performance improvement.
With the guidance now final and revised, the remaining barriers are procedural and cultural — standard operating procedures, inspector expectations, and training. Regulatory uncertainty is no longer the main obstacle.
2. Draft EU Annex 11 focuses on data integrity, suppliers, and security
From July 7, 2025, to October 7, 2025, the European Commission consulted on a draft revision of EU GMP Annex 11. The consultation also covered a revised Chapter 4 and a new Annex 22 on AI. The European Medicines Agency (EMA) GMDP Inspectors Working Group drafted all three with the Pharmaceutical Inspection Co-operation Scheme (PIC/S).
As of October 6, 2026, EudraLex Volume 4 still lists Annex 11 in its January 2011 revision. The 2025 texts remain consultation drafts, and we found no adopted text. Every requirement below can still change.
The draft Annex 11 includes dedicated sections on:
- Supplier and service-provider management.
- Identity and access management, including multifactor authentication for remote access to critical systems from outside controlled perimeters.
- Audit trails that remain “enabled and locked at all times” and get regular review.
- Periodic review after initial validation.
- Information security management.
The draft is also more prescriptive than FDA on test evidence. It expects executed, traceable test scripts, while FDA’s CSA guidance lets manufacturers consider unscripted testing for features that are not high process risk. Teams that validate once for both markets should design test evidence that satisfies both.
The pressure already shows in our survey data. Audit readiness, compliance burden, and data integrity rank as the top three challenges in the 2026 State of Validation, for the third consecutive year.
In practice, digital audit trails and attributable, contemporaneous records under ALCOA++ are becoming the evidence baseline on both sides of the Atlantic.
3. Cloud-based CSV/CSA management and SaaS supplier oversight
Cloud technology is now a vital tool for managing validation activities. Cloud-based validation platforms provide scalability, flexibility, and secure real-time data access, allowing teams to collaborate across sites and time zones. By storing validation data in the cloud, organizations can ensure that all stakeholders have access to the most up-to-date information, which is essential for maintaining compliance and audit readiness.
By implementing your CSV/CSA process using a cloud-based system, companies can also benefit from enhanced data security, automated backups, and simplified disaster recovery. Cloud platforms also enable teams to monitor validation activities remotely, making it easier to oversee complex projects and respond promptly to issues. In our experience, more life sciences companies are moving validation to the cloud for its efficiency and cost savings.
Cloud system validation brings its own challenge: Software as a Service (SaaS) vendors ship updates that customers often cannot defer. FDA’s CSA guidance and GAMP 5 Second Edition both point to leveraging supplier testing and documentation, scaled to risk. Our guide to vendor testing and quality agreements shows how to apply them under CSA and GAMP 5.
FDA’s guidance even includes a worked example for a SaaS product lifecycle management (PLM) system. In practice, regulated companies rely on four controls: supplier assessment, quality agreements, release-note impact assessment, and targeted regression testing, often automated.
Kneat leverages specialized cloud automation processes — like infrastructure-as-code, immutable infrastructure, and containerization — to enhance the delivery of our cloud-based digital validation solution, Kneat Gx and provide an easier, faster, and more responsive validation service.
4. Automation for streamlined CSV/CSA
Automation is also playing an increasingly important role in CSV/CSA, helping organizations streamline processes, reduce human error, and achieve faster results. FDA’s revised CSA guidance, covered in trend one, recognizes automated testing as acceptable objective evidence.
Digital validation systems allow companies to execute CSV/CSA tests online, analyze results, and generate compliance documentation more efficiently than manual methods. By automating routine tasks, validation teams can focus on higher-level activities, such as risk assessment and quality control.
Digital validation minimizes human errors through automation in data entry and analysis, enhancing data accuracy and consistency. Automated systems enforce standardized processes, reducing the risk of errors and discrepancies. This ensures reliable data handling, crucial for strategic decision-making and regulatory compliance.
The vast majority of companies are incorporating digital validation into their long term plans. In the 2026 State of Validation report, 64% of organizations said they were currently using or actively implementing a digital validation solution and 91% had adopted or planned to in the near future.
| Adoption Status | 2026 | 2025 |
|---|---|---|
| Fully adopted | 30% | 16% |
| In progress | 34% | 42% |
| Planning to adopt in <1 year | 13% | 9% |
| Planning to adopt in 1-2 years | 10% | 11% |
| Planning to adopt in 2+ years | 5% | 16% |
| No plans to adopt | 9% | 7% |
The 2026 report also shows full digital adoption rising from 16% to 30%. Workload keeps climbing, too: 80% of 2026 respondents report an increase, matching the 2022 peak. Yet 67% of 2026 respondents say they are more efficient than a year ago, which suggests CSV automation is helping teams absorb the extra demand.
5. AI enters the validation lifecycle — with governance
AI in computer system validation has moved from curiosity to active pilots. In the 2026 State of Validation, 39% of respondents are using or evaluating AI for GxP validation, and 22% are actively deploying it. The share not considering AI fell from 46% to 19%.
Expectations run high: 78% of 2026 State of Validation respondents believe AI will be standard in validation by 2030. Our recap of the validation industry in 2026 lists the early use cases PM Group sees:
- Test script generation and optimization.
- Requirements traceability matrix automation.
- Deviation and test failure classification.
- Document review and compliance checks before human review.
Concerns remain. State of Validation respondents cite accuracy (58%), data security (50%), and hallucinations (45%) as their top AI worries. And 36% are only slightly or not at all familiar with emerging AI regulatory guidance.
FDA’s revised CSA guidance says its approach can be applied to AI and machine learning (ML) tools used in device production or the QMS. GAMP 5 Second Edition’s expanded appendices also cover AI/ML.
Regulatory status as of October 6, 2026: in the EU, Annex 22 on artificial intelligence is still a draft. The July 2025 draft would apply to static models with deterministic outputs in critical GMP applications. It says dynamic models, probabilistic-output models, generative AI, and large language models (LLMs) should not be used in critical applications.
EMA’s workshop report shows the drafting group has discussed widening that scope. Until the text settles, human oversight is the practical control.
Treat every AI output as a draft that a qualified subject matter expert (SME) reviews and approves. Keep human-in-the-loop sign-off, traceability, and ALCOA++ records for each decision.
Kneat Gx includes optional AI capabilities built on its ALCOA++ data integrity controls. Kneat groups them into four areas — Generate, Review, Interrogate, and Develop — with human oversight aligned with GAMP 5 good practice. Our whitepaper on AI in validation governance sets out five pillars of a validated AI environment.
6. Integration of CSV/CSA with CI/CD pipelines
As life sciences organizations adopt Continuous Integration and Continuous Delivery (CI/CD) practices, integrating CSV/CSA into these pipelines is, in our experience, a growing priority. CI/CD pipelines automate the testing and deployment of software changes, allowing for faster and more frequent releases. By incorporating CI/CD into the CSV/CSA process, companies can validate their systems on an ongoing basis, ensuring that each new release meets regulatory requirements.
Integrating CSV/CSA with CI/CD pipelines also supports agile development, as validation tests are triggered with each change. This reduces the time required for final system validation, as potential issues are identified and addressed early in the development cycle. For organizations looking to accelerate product releases while maintaining compliance, this trend offers a strategic advantage.
“Kneat offers a full compliant and traceable solution. From User Requirements to UAT, everything is connected., making validation process much easier,” an IT engineer working in Healthcare said of Kneat.
7. Using Agile methodology for faster validation cycles
In our experience, Agile methodology is gaining traction in life sciences, and CSV/CSA is no exception. Agile emphasizes iterative development, continuous feedback, and rapid adaptability, making it well-suited for dynamic environments like validation. By adopting Agile principles, organizations can break down validation tasks into smaller, manageable sprints, allowing teams to address issues and adjust quickly.
Using an Agile development approach as part of your CSV/CSA process enables more efficient project management and reduces the time required for validation by focusing on short, focused validation cycles. This approach also allows validation teams to collaborate closely with development teams, ensuring that validation activities are aligned with system changes. For organizations looking to reduce validation cycle times and respond more effectively to regulatory updates, Agile offers a flexible and responsive solution.
Founder and CEO of ProcellaRx spoke to Kneat’s Agile capabilities:
When you start to use a tool like Kneat and have the ability to bridge different groups together from cleaning validation to CQ to CSV and others, you then have the ability to tap into each part of that, because you’re keeping that holistically within one platform.
Kneat customer Fujirebio shrunk their review cycle times by 50% using Kneat, including 40% fewer hours spent on test execution and faster review times.
ISPE GAMP5® Second Edition includes Appendix D8, Agile Software Development. It explains how teams can apply Agile practices while meeting GxP requirements.
8. Using data visualization tools for effective CSV/CSA analysis
Data visualization tools are becoming indispensable in CSV/CSA, as they allow validation teams to quickly identify trends, spot anomalies, and make data-driven decisions. Visual representations of validation data enable teams to monitor progress, track key performance indicators, and assess the impact of validation efforts in real time. Data visualization also supports regulatory audits, as it provides clear, easy-to-understand insights into validation activities.
By using dashboards and other visualization tools, organizations can simplify complex data sets and gain a complete view of their validation status. This enhances decision-making and improves the ability to communicate validation findings with stakeholders, from regulatory bodies to internal leadership. As the demand for real-time insights grows, data visualization will continue to be a valuable asset in the CSV/CSA toolkit.
Our digital validation platform Kneat Gx delivers at-a-glance insights into every aspect of the validation process across all facilities in real time. You can instantly see if a system is validated, due for review, in review, and more. Business Intelligence dashboards unlock deeper insights including document statuses, user workloads, work processes status updates, across all validation disciplines.
Advanced filter and search functionality complete with preview snippets allows for easy and flexible searching of documents, drawings, files, attachments, and other relevant assets.
Reporting and paperless handover in Kneat Gx
Within Kneat Gx you can run status reports for all projects, systems, and validation deliverables and create a report using filters. Filtered reports are saved and exported to PDF.
“Decisions are now data driven and we have alignment across various softwares using this dashboard,” according to one Kneat customer.
Paperless handover makes it easy to present documentation outside of Kneat Gx — perfect for administrative tasks — while including a full audit trail of all activities.
What software helps computer system validation?
Digital validation software helps computer system validation by managing requirements, risk, testing, approvals, and evidence in one compliant system. It turns the computer system validation trends above into everyday controls. Look for these capabilities:
- Electronic records, e-signatures, and audit trails that meet 21 CFR Part 11 and Annex 11 (trend two).
- Risk-based test scoping with both scripted and unscripted test capture (trend one).
- Real-time requirements traceability from each requirement to its test evidence (trends one and four).
- Supplier evidence and change impact management for SaaS releases (trend three).
- Periodic review scheduling and validation-status dashboards (trend eight).
- Governed, human-in-the-loop AI with traceable outputs (trend five).
- Open integration with QMS, learning management system (LMS), and enterprise resource planning (ERP) tools (trends four and eight).
Nine of the world’s top 10 life sciences companies use Kneat Gx, a configurable, paperless digital validation platform. Its real-time Requirements Traceability Matrix (RTM) updates automatically as users save changes. Re-executable testing removes redundant approval steps for repeat tests while preserving audit trails.
Fujirebio Diagnostics needed CSV that could handle 30–40 computer systems per year. After digitalizing CSV in Kneat Gx, the team cut corrective and preventive action (CAPA) change control time by 53%. It also needs 40% fewer hours for test script execution.
Final thoughts
CSV/CSA is evolving rapidly, driven by regulatory change, technology, and modern methodologies that prioritize efficiency and compliance. FDA’s revised CSA guidance and the draft EU Annex 11 and Annex 22 now shape how teams scope, test, and document. SaaS supplier oversight, automation, governed AI, CI/CD, Agile, and data visualization are the computer system validation trends helping organizations streamline validation and enhance data integrity.
As organizations incorporate these trends into their CSV/CSA processes, they are better positioned to meet regulatory requirements, reduce operational costs, and enhance overall validation effectiveness.
Our digital validation software Kneat Gx digitalizes the entire CSV/CSA lifecycle, delivering compelling productivity, cycle time, and compliance improvements.
Join us for an exclusive demo and discover how our solution supports the latest trends and makes CSV and CSA faster, easier, and more compliant.
